184 related articles for article (PubMed ID: 8718426)
21. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Murad AM
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
[TBL] [Abstract][Full Text] [Related]
22. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Anderson H; Lund B; Bach F; Thatcher N; Walling J; Hansen HH
J Clin Oncol; 1994 Sep; 12(9):1821-6. PubMed ID: 8083706
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
Zatloukal P; Kanitz E; Magyar P; Jassem J; Krzakowski M; Pawlicki M; Petruzelka L; Chovan L; Pesek M; Janko C; Krejcy K
Lung Cancer; 1998 Dec; 22(3):243-50. PubMed ID: 10048477
[TBL] [Abstract][Full Text] [Related]
24. Safety profile of gemcitabine.
Tonato M; Mosconi AM; Martin C
Anticancer Drugs; 1995 Dec; 6 Suppl 6():27-32. PubMed ID: 8718422
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
Lund B; Hansen OP; Theilade K; Hansen M; Neijt JP
J Natl Cancer Inst; 1994 Oct; 86(20):1530-3. PubMed ID: 7932808
[TBL] [Abstract][Full Text] [Related]
27. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
28. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
29. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine and vinorelbine combination in patients with metastatic breast cancer.
Sanal SM; Gokmen E; Karabulut B; Sezgin C
Breast J; 2002; 8(3):171-6. PubMed ID: 12047474
[TBL] [Abstract][Full Text] [Related]
31. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
Athanasiadis A; Roussos G; Papakostoulis T; Athanasiadou DC; Stathopoulos GP
Cancer Chemother Pharmacol; 2005 Dec; 56(6):653-8. PubMed ID: 15937714
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine: a phase II study in patients with advanced renal cancer.
De Mulder PH; Weissbach L; Jakse G; Osieka R; Blatter J
Cancer Chemother Pharmacol; 1996; 37(5):491-5. PubMed ID: 8599874
[TBL] [Abstract][Full Text] [Related]
34. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study.
Takada M; Negoro S; Kudo S; Furuse K; Nishikawa H; Takada Y; Kamei T; Niitani H; Fukuoka M
Cancer Chemother Pharmacol; 1998; 41(3):217-22. PubMed ID: 9443638
[TBL] [Abstract][Full Text] [Related]
35. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
[TBL] [Abstract][Full Text] [Related]
36. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
[TBL] [Abstract][Full Text] [Related]
37. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
Manegold C; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen P; Liippo K; Mattson K; van Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; van Walree N; ten Bokkel-Huinink W
Ann Oncol; 1997 Jun; 8(6):525-9. PubMed ID: 9261520
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.
Sessa C; Aamdal S; Wolff I; Eppelbaum R; Smyth JF; Sulkes A; Ten Bokkel Huinink W; Vermorken J; Wanders J; Franklin H
Ann Oncol; 1994 May; 5(5):471-2. PubMed ID: 8075055
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
[TBL] [Abstract][Full Text] [Related]
40. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
